I fully understand the pharmaceutical industry’s frustration with NICE – it stops them making so much money at taxpayers expense. What I don’t understand is why we are paying them any attention.

Comment from FinPhil in the FT. Most recent egregious example of pharma here, although this is not the NICE example. 2016 was the year when pharma began to boast about  their new ‘we do not need to invent drugs’ financial model. Then they got embarrassed, as commentators like Martin Wolf of the FT pointed out that many people now  viewed pharma like they viewed bankers. Financial engineering is much easier than biological engineering.